Streamex Corp. reported significant financial changes in its latest quarterly filing for the period ending March 31, 2026. The company, which transitioned from BioSig Technologies, Inc. following its acquisition of Streamex Exchange Corporation in May 2025, recorded no revenue for the quarter, consistent with the same period in the previous year. However, total operating expenses surged to $35.7 million, a substantial increase from $3 million in the first quarter of 2025. This rise was primarily driven by a 1,200% increase in general and administrative expenses, which reached $34.3 million, largely due to stock-based compensation and increased professional fees associated with the company's expanded operations.

The company's net loss for the quarter was $46.7 million, compared to a loss of $2.8 million in the same quarter of the previous year. This increase in loss was attributed to higher operating expenses and significant interest expenses related to the company's convertible debentures, which were settled in February 2026. The company recognized a realized loss of $3.1 million on the extinguishment of these debentures, which included a cash payoff and the conversion of a portion into common stock. The net loss attributable to common shareholders was $46.7 million, translating to a loss per share of $0.27, compared to a loss of $0.14 per share in the prior year.

In terms of operational developments, Streamex Corp. has made strides in its strategic initiatives, particularly in the tokenization of real-world assets. The company acquired approximately $15.2 million worth of gold bullion to support its GLDY Token program, which aims to provide token holders with exposure to gold. As of March 31, 2026, Streamex held approximately 98.5% of the outstanding GLDY Tokens. The company also reported that two related party officers subscribed for a total of $225 in GLDY Tokens during March 2026. Despite these developments, the company has yet to generate material revenue from its new digital asset infrastructure.

Streamex Corp. has strengthened its liquidity position, ending the quarter with $6.9 million in cash and working capital of approximately $42.6 million. This was bolstered by net proceeds of $37.2 million from an underwritten public offering completed in January 2026, alongside cash generated from the sale of marketable securities and gold bullion. The company has eliminated its outstanding convertible debt, which is expected to improve its financial flexibility moving forward. However, management anticipates continued operating losses and negative cash flows until its products achieve sustained commercial success, particularly the Streamex Exchange platform and the PURE EP™ initiatives.

Looking ahead, the company remains focused on the commercialization of its digital asset infrastructure and the development of its tokenization solutions. Management has indicated that future revenues will depend on various factors, including market conditions, regulatory developments, and the successful adoption of its offerings. The company believes it has sufficient liquidity to meet its operational needs for at least the next year, but it will continue to evaluate additional capital sources to support its growth strategy.

About BioSig Technologies, Inc.

BioSig Technologies, Inc. develops advanced medical device technology focused on electrophysiology (EP) with its PURE EP™ Platform, which enhances real-time cardiac signal acquisition and analysis during catheter ablation of complex arrhythmias like atrial fibrillation and ventricular tachycardia. Serving electrophysiologists and EP labs, BioSig’s platform improves signal clarity and procedural precision, aiming to optimize ablation outcomes through proprietary hardware and software integrated into existing clinical workflows.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.